How to Meet the Market Cap/Revenue Test for a Hong Kong Listing Without Profits

The calculus for pre-revenue or low-profit Chinese companies seeking a Hong Kong listing has shifted decisively since the HKEX’s Chapter 18C reforms took full effect on 31 March 2023, followed by the 18B specialist technology regime adjustments in September 2024. The old binary of “must show three years of consistent profits” no longer applies for issuers meeting the Market Cap/Revenue test under Listing Rules 8.05(1)(b) and 8.09(2). According to the HKEX’s 2024 annual review of listing applications, 27% of new Main Board listings in the 12 months to 30 June 2024 relied on this test, up from 11% in the comparative period before the reform. For Chinese concept stocks (中概股) with strong revenue growth but negative net margins — common in biotech, SaaS, and new-economy sectors — this pathway is now the primary route to a dual-primary or secondary listing. The market cap requirement of HKD 4 billion (approximately USD 512 million at current exchange rates) and a revenue threshold of HKD 1 billion for the most recent financial year create a high bar, but one that is mechanically achievable through proper structuring of VIE (Variable Interest Entity) consolidations, revenue recognition under HKFRS 15, and pre-IPO capital raising that inflates market capitalisation without requiring a public trading history. This article dissects the exact HKEX Listing Rule provisions, the sponsor’s burden of proof, and the PRC regulatory overlay from the CSRC’s December 2023 filing rules to show how an issuer can satisfy the test.

The Mechanics of the Market Cap/Revenue Test Under HKEX Listing Rules 8.05 and 8.09

The Market Cap/Revenue test is codified in HKEX Main Board Listing Rule 8.05(1)(b), which requires an issuer to demonstrate a market capitalisation of at least HKD 4 billion at the time of listing and revenue of at least HKD 1 billion for the most recent financial year. The test is one of three alternative financial eligibility criteria under Rule 8.05, alongside the Profit Test (Rule 8.05(1)(a): HKD 80 million aggregate profit over three years) and the Market Cap/Revenue/Cash Flow Test (Rule 8.05(1)(c): HKD 2 billion market cap, HKD 500 million revenue, and HKD 100 million positive cash flow). The critical distinction of the Market Cap/Revenue test is that it imposes no profit requirement and no cash flow requirement — only size and top-line revenue.

The HKD 4 Billion Market Capitalisation Requirement: How It Is Calculated and Proved

The market capitalisation under Rule 8.05(1)(b) is determined by reference to the issue price in the prospectus, multiplied by the total number of shares in issue immediately after the global offering (including any over-allotment shares under the Greenshoe mechanism). This means the sponsor must project a market cap at listing that is at least HKD 4 billion, based on the offer price range and the fully diluted share count. The HKEX’s Listing Decision LD115-2023 clarified that the market cap calculation must exclude any shares that are subject to lock-up restrictions that would prevent them from being freely traded immediately, but the total issued shares include those held by pre-IPO investors, founders, and employees under share schemes.

For a pre-revenue company, achieving this HKD 4 billion threshold typically requires a pre-IPO funding round at a valuation of HKD 4.5 billion to HKD 5.5 billion, providing a buffer against the 15% to 20% discount that is standard in Hong Kong IPOs compared to the last private round. Data from Refinitiv for 2024 shows that the median discount for Chinese concept stock IPOs on the Main Board was 18.7% relative to the last pre-IPO valuation. The sponsor must submit a valuation report from an independent valuer (commonly a Big Four firm or a specialist like Duff & Phelps) that supports the pre-IPO valuation, using methodologies such as discounted cash flow (DCF), comparable company analysis (CCA), or precedent transactions. The SFC’s Code of Conduct for Sponsors (paragraph 17.2) requires the sponsor to verify the reasonableness of the valuation assumptions, including revenue growth rates, terminal value multiples, and discount rates.

The HKD 1 Billion Revenue Threshold: Revenue Recognition Under HKFRS 15

The revenue threshold of HKD 1 billion for the most recent financial year is subject to full audit by the reporting accountant (typically a Big Four firm) under Hong Kong Financial Reporting Standards (HKFRS). For VIE-structured Chinese companies, revenue is consolidated under HKFRS 10, which requires the issuer to demonstrate control over the VIE through contractual arrangements rather than equity ownership. The HKEX’s Guidance Letter HKEX-GL112-22 (updated January 2024) explicitly requires sponsors to assess whether the VIE structure is legally enforceable under PRC law and whether the revenue generated by the VIE can be attributed to the listed issuer under the consolidation rules.

Revenue recognition for SaaS and biotech companies is particularly scrutinised. The SFC’s 2023 thematic review of revenue recognition in IPO prospectuses found that 34% of applications had material deficiencies in recognising revenue from contracts with multiple performance obligations (e.g., software licences bundled with implementation services). Under HKFRS 15, the issuer must allocate the transaction price to each distinct performance obligation and recognise revenue when control transfers to the customer. For a SaaS company with annual recurring revenue (ARR) of HKD 1.2 billion, the sponsor must prove that the portion of ARR attributable to non-cancellable contracts is at least HKD 1 billion, net of any refund liabilities or variable consideration adjustments.

Structuring the VIE and Pre-IPO Capital Raising to Support the Test

The VIE structure remains the dominant vehicle for Chinese concept stocks listing in Hong Kong, despite the PRC’s December 2023 filing rules under the CSRC’s Trial Administrative Measures of Overseas Securities Offering and Listing. The CSRC requires all VIE-structured companies to file a registration statement within three business days of submitting the A1 application to HKEX, and the filing must include a legal opinion from PRC counsel confirming that the VIE structure does not violate any explicit prohibitions in the Negative List for Foreign Investment Access (2024 edition). The HKEX’s Listing Rule 8A.04 requires the listed issuer to have a controlling shareholder with at least 30% of the voting rights, which in a VIE structure is typically the founder through a BVI or Cayman holding company.

Pre-IPO Funding Rounds: Valuation Mechanics and Lock-Up Agreements

To achieve the HKD 4 billion market cap, the issuer must complete at least one pre-IPO funding round with a valuation that exceeds the implied IPO market cap after the discount. The typical structure involves a series of preferred share issuances in the Cayman Islands holding company, with each round priced at a per-share valuation that implies a post-money valuation of HKD 5 billion or more. For example, in the 2024 IPO of a Chinese biotech company (case study: Jiangsu Hengrui Medicine’s Hong Kong listing was structured with a pre-IPO valuation of HKD 8 billion, leading to a listing market cap of HKD 6.2 billion), the pre-IPO investors included sovereign wealth funds and healthcare-focused PE firms.

The lock-up agreements under HKEX Listing Rule 10.07 require all pre-IPO investors to hold their shares for at least six months from the listing date, and the controlling shareholder must lock up for 12 months. However, the market cap calculation at listing includes these locked-up shares, provided they are ordinary shares with full economic and voting rights. The sponsor must ensure that the pre-IPO subscription agreements do not contain any put options or redemption rights that would trigger a liability under HKFRS 32 (financial instruments classification), as such rights could reduce the equity classification and affect the market cap calculation.

Revenue Consolidation Through the VIE: The HKFRS 10 Control Test

The revenue of the VIE is consolidated into the listed issuer’s financial statements only if the issuer can demonstrate control under HKFRS 10. The control test requires power over the VIE, exposure to variable returns, and the ability to use power to affect those returns. For a typical VIE structure, the power is derived from the exclusive technical service agreement, the equity pledge agreement, and the call option agreement, all governed by PRC law. The HKEX’s GL112-22 requires the sponsor to obtain a legal opinion from a qualified PRC law firm confirming that these agreements are enforceable in a PRC court.

A critical issue is revenue attribution: if the VIE generates HKD 1.2 billion in revenue from its operating subsidiaries (e.g., a Chinese edtech company with online courses), the listed issuer (the Cayman holding company) must recognise this revenue as its own under the consolidation rules. The PRC operating subsidiaries are typically wholly foreign-owned enterprises (WFOEs) that hold the intellectual property and provide services to the VIE, but the revenue flows through the VIE structure via service fees. The sponsor must show that the service fees are set at arm’s length and that the WFOE has the substantive economic substance to justify the revenue attribution. The SFC’s 2024 enforcement action against a Chinese fintech issuer (SFC v. [Redacted], HCMP 1234/2024) highlighted that revenue inflation through artificial service fees was a material misrepresentation, leading to the suspension of the listing application.

Sponsor Verification and Regulatory Scrutiny from the HKEX and SFC

The sponsor’s verification burden under the Market Cap/Revenue test is significantly higher than under the Profit Test, because the sponsor must prove the sustainability of the revenue stream and the reasonableness of the market cap. The SFC’s Code of Conduct for Sponsors (paragraph 17.1) requires the sponsor to conduct due diligence on the issuer’s business model, revenue drivers, and customer concentration. For a company with HKD 1 billion in revenue but negative profits, the sponsor must also assess whether the revenue is recurring and whether the issuer has a viable path to profitability within a reasonable timeframe, as per the HKEX’s Guidance Letter HKEX-GL86-16.

The HKEX’s Discretion to Impose Additional Conditions Under Rule 8.05(2)

HKEX Listing Rule 8.05(2) gives the Exchange discretion to impose additional conditions on an issuer that relies on the Market Cap/Revenue test, including requiring a higher market cap, a longer trading record, or additional disclosure in the prospectus. In practice, the HKEX has applied this discretion in approximately 15% of Chapter 18C applications in 2024, according to the HKEX’s own statistics. Common additional conditions include a requirement for the issuer to provide quarterly revenue updates for the first two years post-listing, or a requirement for the sponsor to retain an independent financial adviser for the first 12 months.

The HKEX’s Listing Committee has also shown a willingness to reject applications where the revenue is concentrated in a single customer or a small number of customers. In a 2024 Listing Committee decision (HKEX-LD-124-2024), the Committee rejected a biotech issuer’s application under the Market Cap/Revenue test because 78% of its HKD 1.1 billion revenue came from one distributor in the PRC, and the sponsor could not verify the end-user demand. The Committee required the issuer to wait until the next financial year to demonstrate revenue diversification.

The CSRC Filing Requirement and PRC Regulatory Overlay

The CSRC’s December 2023 filing rules require all Chinese companies seeking an overseas listing to file a registration statement within three business days of submitting the A1 application to HKEX. For VIE-structured issuers, the CSRC requires a legal opinion confirming that the VIE structure does not violate the Negative List for Foreign Investment Access (2024 edition). The Negative List prohibits foreign investment in certain sectors, including internet content provision (ICP licensing) and some healthcare services. If the issuer’s VIE operates in a restricted sector, the CSRC may require a restructuring to remove the VIE or to convert it to a wholly owned structure.

The CSRC’s review timeline is typically 20 working days for a standard filing, but it can extend to 60 working days if the CSRC raises questions. In 2024, the CSRC rejected or delayed 12 VIE-structured filings, according to a report by the China Securities Journal. The sponsor must factor this timeline into the A1 submission date, as any CSRC delay will push the HKEX hearing date back. The HKEX’s Listing Rule 8.01(1) requires the issuer to have all necessary PRC regulatory approvals before listing, and the CSRC filing is now a de facto requirement.

Actionable Takeaways for Issuers and Sponsors

1. Target a pre-IPO valuation of at least HKD 5 billion to provide a 20% buffer against the standard IPO discount, ensuring the HKD 4 billion market cap threshold is met even if the offer price is at the bottom of the range.
2. Ensure revenue recognition under HKFRS 15 is fully audited and documented at least six months before the A1 filing, with a specific focus on multiple performance obligations and variable consideration for SaaS and biotech issuers.
3. Diversify the customer base to avoid concentration risk, as the HKEX’s Listing Committee has rejected applications where a single customer accounted for more than 50% of HKD 1 billion revenue, even if the total revenue threshold is met.
4. Engage PRC legal counsel to prepare the CSRC filing and VIE enforceability opinion at least three months before the A1 submission, as the 20 to 60 working day review timeline can derail the listing schedule.
5. Prepare a detailed revenue sustainability analysis for the sponsor’s due diligence report, demonstrating that the HKD 1 billion revenue is recurring and that the issuer has a credible path to positive EBITDA within three years, as the SFC will scrutinise this even though the test does not require profits.